| Patient | Eva Perón |
|---|---|
| Date of birth | 1919-05-07 |
| Identifiers | MRN HR-ML025-SYN-TD; SSN (made up) 000-25-7316 |
| Document date | 1951-03-02 |
| Author | Lucía Barragán, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Staging results and treatment decisions. [S]
Ms. Perón returns two weeks after the diagnosis, in Spanish, to hear her staging results with Dr. Barragán and Dr. Osei-Bonsu, with the interpreter. She came alone by choice. She has thought about the fertility options and does not want to delay treatment for egg freezing or have an operation to move her ovaries; she understands that she will not be able to carry a pregnancy and that early menopause is likely, and is at peace with that decision. She has told a close friend and one colleague, and will tell her family herself. Bleeding is light, the pelvic ache is 3 of 10 with acetaminophen, and she has more energy since starting iron. Radiation planning was done three days ago. [S]
| Element | Detail |
|---|---|
| Staging | Pelvic MRI and PET-CT done; HIV and hepatitis C negative |
| Fertility decision | Declined egg freezing and ovarian transposition; does not want treatment delayed |
| Who knows | A friend and a colleague; she will tell her family herself |
| Symptoms | Light bleeding; pelvic ache 3 of 10; more energy |
| Scores | PHQ-9 8; GAD-7 7 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; no fever or weight loss |
| Genitourinary | Positive | Light bleeding; no urinary symptoms |
| Musculoskeletal | Negative | No back pain or leg swelling |
| Psychiatric | Positive | Anxious about treatment but hopeful; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy | One tablet by mouth once daily | Oral route | 1951-02-09 to 1951-08-17 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day | One or two tablets every 6 hours when needed, no more than 6 a day | Oral route | 1951-02-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1951-03-02 | Body height | 165 | cm | S |
| 1951-03-02 | Body weight | 52.5 | kg | S |
| 1951-03-02 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 1951-03-02 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1951-03-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1951-03-02 | Heart rate | 84 | /min | S |
| 1951-03-02 | Respiratory rate | 14 | /min | S |
| 1951-03-02 | Body temperature | 36.7 | Cel | S |
| 1951-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1951-03-02 | Hemoglobin [Mass/volume] in Blood | 10.2 | g/dL | 11.6-15 g/dL | Low | S |
| 1951-03-02 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 77 | fL | 80-100 fL | Low | S |
| 1951-03-02 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1951-03-02 | Platelets [#/volume] in Blood by Automated count | 352 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1951-03-02 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 1951-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1951-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
Vital signs recorded on 1951-03-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Less pale; pulse 84, blood pressure 110/68 |
| Abdomen | Soft; no mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Psychiatric | Calm and engaged; asks about the treatment schedule |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation booked | resolved | confirmed | N93.8 | S — Synthetic presenting problem linked to her documented abnormal bleeding with anemia; superseded by the diagnosis at the consultation. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding linked to her documented anemia from vaginal bleeding. |
| Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 1943 staging. Synthetic modern episode linked to her documented cervical cancer | active | confirmed | C53.9 | S — Synthetic modern diagnosis made at the gynecologic oncology consultation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Disclosure and information preferences: she is told first, in Spanish, as much as she wants to know; she decides who else is told | Every visit | Completed today | Stage and likely outcome explained in Spanish; she chose to come alone and has told those she wished to |
| Imaging | Pelvic MRI | At staging, for local extent | Up to date | Six days ago: left parametrial invasion, no pelvic wall, upper vagina only, no hydronephrosis or nodes |
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Up to date | Four days ago: cervix only; no nodal or distant uptake. Next about three months after treatment |
| Laboratory | HIV and hepatitis C tests | At diagnosis | Up to date | HIV and hepatitis C negative |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 10.2 g/dL, mean cell volume 77 fL, white cells 6.8, platelets 352 |
| Laboratory | Kidney function (creatinine, eGFR) and magnesium for cisplatin | Before cisplatin, weekly during it, and after | Up to date | Creatinine 0.7 mg/dL two weeks ago; weekly during cisplatin |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 3 of 10 on acetaminophen; no anti-inflammatory painkillers |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Completed today | PHQ-9 8 (item 9 scored 0), GAD-7 7 |
| Referral | Fertility and ovarian function counseling and her decision | Before cancer treatment begins | Completed today | She declined egg freezing and ovarian transposition after counseling |
| Referral | Oncology social worker and spiritual care | At diagnosis and through treatment | Completed today | Social worker weekly during treatment; help with a reduced work schedule |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027); Revised FIGO staging for carcinoma of the cervix uteri (2018 (published 2019)); Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline (2017); Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018); Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)
Follow-up: Chemoradiation starts in one week, with weekly reviews by the oncology team. Review here two weeks after brachytherapy. Next scheduled visit 1951-05-18: review two weeks after completing chemoradiation and brachytherapy: side effects, menopause symptoms, and survivorship care. [S]